[Evaluation of alpha-normiks (rifaximin) efficacy in the treatment of patients with diverticular disease associated with medium and severe intestinal dysbacteriosis].
OBJECTIVE
to evaluate the efficacy of using rifaksimin drug within complex therapy of patients with the disease and diverticular intestinal dysbacteriosis.


METHODS
57 patients participated with a moderate exacerbation of the disease, they were divided equally on the composition of the group--two control and one under study. Patients in the control groups were composed of complex treatment of oral antibacterial drugs, or bacteriophage, the investigated group of patients--rifaksimin. We evaluated the dynamics of clinical symptoms, analysis of stool for dysbacteriosis and biochemical parameters.


RESULTS
detected superior effectiveness of the Alpha-normiks drug in the treatment of patients with colon pathologies investigated in comparison with the use of oral antibacterial drugs, or bacteriophages. Proved the high safety of treatment with using of rifaksimin.


CONCLUSIONS
The preparation of Alpha-normiks may be appointed with great success at patients with diverticular disease, and with intestinal dysbacteriosis.
Lutkov
I V
IV
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D043963:Diverticulosis, Colonic / Q000188:drug therapy* / Q000382:microbiology; D004359:Drug Therapy, Combination; D006801:Humans; D007422:Intestines / Q000187:drug effects / Q000382:microbiology*; D012294:Rifamycins / Q000008:administration & dosage / Q000627:therapeutic use*; D000078262:Rifaximin; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D012294:Rifamycins; D000078262:Rifaximin